Gruticibart is under clinical development by Aronora and currently in Phase II for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). According to GlobalData, Phase II drugs for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gruticibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gruticibart (AB-023) is under development for the treatment of cardiovascular disease, thrombosis, neurological disorders and end-stage renal disease. The drug candidate is administered through intravenous route. It is a recombinant monoclonal antibody that selectively targets assembly of the blood contact activation complex.
Aronora operates in pharmaceutical and healthcare industry. It is headquartered in United States.
For a complete picture of Gruticibart’s drug-specific PTSR and LoA scores, buy the report here.